{Reference Type}: Journal Article
{Title}: [Research Progress on Predictive Biomarkers of Immunotherapy Efficacy
in Non-small Cell Lung Cancer].
{Author}: Sun T;Chen Z;Wei K;Tang H;
{Journal}: Zhongguo Fei Ai Za Zhi
{Volume}: 27
{Issue}: 6
{Year}: 2024 Jun 20
暂无{DOI}: 10.3779/j.issn.1009-3419.2024.106.12
{Abstract}: Lung cancer is one of the most common malignant tumors in the world, of which non-small cell lung cancer (NSCLC) is the majority. The emergence of immune checkpoint inhibitors (ICIs) has greatly changed the treatment strategy of NSCLC and improved the prognosis of patients. However, in reality, only a small number of patients can achieve long-term benefit. Therefore, the identification of reliable predictive biomarkers is essential for the selection of treatment modalities. With the development of molecular biology and genome sequencing technology in recent years, as well as the in-depth understanding of tumor and its host immune microenvironment, research on biomarkers has emerged in an endless stream. This review focuses on the predictive biomarkers of immunotherapy efficacy in NSCLC, in order to provide some guidance for precision immunotherapy.
.<BR>【中文题目：非小细胞肺癌免疫治疗疗效的
预测生物标志物研究进展】 【中文摘要：肺癌是世界上最常见的恶性肿瘤之一，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）占大多数。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的出现极大地改变了NSCLC的治疗策略，并改善了患者预后，然而现实中只有少部分患者能够获得长期受益。因此，确定可靠的预测生物标志物对选择治疗方式至关重要。随着近年来分子生物学、基因组测序技术的发展以及对肿瘤及其宿主免疫微环境的认识不断深入，生物标志物的研究层出不穷。本文围绕NSCLC免疫治疗疗效的预测生物标志物进行综述，以期为精准免疫治疗提供指导。
】 【中文关键词：肺肿瘤；免疫治疗；肿瘤突变负荷；生物标志物；预测】.